Name: Latest research reports of Eris Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Mid-range Performer

1585.5000 -40.60 (-2.50%)

NSE Sep 26, 2025 15:31 PM

44.50% Gain from 52W Low

Volume: 67,085

Eris Lifesciences Ltd.

26 Oct 2024

1585.50

-2.50%

Eris Lifesciences (BUY): Fully vertically integrated biologics segment; maintain BUY

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

Q2 revenue/PAT above our estimates due to better traction in both base and acquired businesses

Number of FII/FPI investors increased from 178 to 193 in Jun 2025 qtr.